American Society for Microbiology, Applied and Environmental Microbiology, 4(79), p. 1126-1133, 2013
DOI: 10.1128/aem.02792-12
Full text: Download
ABSTRACT Anidulafungin, which noncompetitively inhibits β-(1,3)- d -glucan synthase in fungal cell wall biosynthesis, is the newest antifungal drug to be developed. Echinocandin B deacylase from Actinoplanes utahensis NRRL 12052 catalyzes the cleavage of the linoleoyl group of echinocandin B, a key step in the process of manufacturing anidulafungin. Unfortunately, the natural yield of echinocandin B nucleus is low. In our study, the echinocandin B deacylase gene was systematically overexpressed by genetic engineering in its original producer, A. utahensis , and in the heterologous hosts Streptomyces lividans TK24 and Streptomyces albus . The introduction of additional copies of the gene, under the control of PermE * or its native promoter, into hosts showed significant increases in its transcription level and in the efficiency of the bioconversion of echinocandin B to its nucleus. The conditions for the cultivation and bioconversion of A. utahensis have been optimized further to improve production. As a result, while the wild-type strain initially produced 0.36 g/liter, a concentration of 4.21 g/liter was obtained after the generation of a strain with additional copies of the gene and further optimization of the reaction conditions. These results are useful for enhancing echinocandin B nucleus production in A. utahensis . Our study could enable the engineering of commercially useful echinocandin B nucleus-overproducing stains.